10-K: China Foods Holdings Ltd. Reports Annual Results for Fiscal Year Ended December 31, 2024

China Foods Holdings Ltd. reports a net loss of $455,571 for the fiscal year ended December 31, 2024, amid revenue growth and strategic business developments.

Summary

• China Foods Holdings Ltd., a health and wellness company, released its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company reported revenues of $233,339 for 2024, compared to $158,475 in 2023, representing a 47% increase.
• The net loss for the year was $455,571, an increase from the $403,700 loss in the previous year.
• The company operates through two segments: Healthcare and Wine.
• The Healthcare segment focuses on health consulting and wellness products, while the Wine segment provides wine products.
• The company is implementing strategies to expand distribution channels, strengthen marketing, and broaden its product range.
• The company faces risks related to operating in China, including evolving regulations and potential government oversight.
• The company's auditor for the year ended December 31, 2024 was J&S Associate PLT.
• The company's management has concluded that, as of December 31, 2024, its internal control over financial reporting was not effective.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with revenue growth offset by increased losses and concerns about internal controls. The company is taking steps to improve its business, but significant challenges remain.

Positives

• The company experienced a 47% increase in revenue, indicating growth in its business operations.
• The company is actively pursuing strategies to expand its market share and improve efficiency.
• The Great Health Industry in China is experiencing significant growth, presenting opportunities for the company.
• The company is focused on developing both online and offline distribution channels to increase sales volume and revenue.

Negatives

• The company incurred a net loss of $455,571, indicating ongoing financial challenges.
• The company's cost of revenue as a percentage of net revenue increased, impacting gross profit.
• The company's management has concluded that, as of December 31, 2024, its internal control over financial reporting was not effective.
• The company's accumulated deficit was $2,131,544 as of December 31, 2024.

Risks

• The company faces risks related to operating in China, including evolving regulations and potential government oversight.
• Uncertainties in the interpretation and enforcement of Chinese laws could have a material adverse effect.
• The company's ability to continue as a going concern is dependent upon improving its profitability and the continuing financial support from its major shareholders.
• The company's management has concluded that, as of December 31, 2024, its internal control over financial reporting was not effective.

Future Outlook

The company is focused on achieving long-term growth in revenues, cash flow, and profit by developing multiple distribution channels, strengthening marketing and promotions, and broadening its product range.

Management Comments

• Our business experienced steady growth this year, driven by improving market conditions and increased demand for our services.
• We have continued to refine our operational strategies, enhance efficiency, and capitalize on emerging opportunities.
• While challenges remain, we remain committed to sustainable growth and operational excellence.

Industry Context

The Great Health Industry in China is an emerging industry with huge market potential, projected to exceed USD4.03 trillion by 2030, presenting significant opportunities for companies in this sector.

Comparison to Industry Standards

• The company competes with leading e-commerce companies such as Alibaba (China) and businesses such as UNI HEALTH (HK stock code: 02211) and ALI HEALTH (HK stock code:0241).
• These competitors have longer operating histories, significantly greater financial, technical, marketing and other resources, larger product and services offerings, larger customer base and greater brand recognition.

Management Changes

Related Party Transactions

• From time to time, the Company's directors, related parties and related company advanced funds to the Company for working capital purpose.
• Those advances are unsecured, non-interest bearing and due on demand.

Stakeholder Impact

• Shareholders: The increased net loss may negatively impact shareholder value.
• Employees: The company's efforts to improve efficiency and expand may create opportunities for employees.
• Customers: The company's focus on broadening its product range and improving customer engagement may benefit customers.
• Creditors: The company's ability to repay debts depends on its ability to improve profitability and secure additional financing.

Next Steps

• The company intends to develop both online and offline distribution channels to increase sales volume and revenue.
• The company intends to partner with third party e-commerce platforms, social media and We-media such as Wechat, TikTok and Xiaohongshu to build our online presence.
• The company intends to create a one-stop solution for our customers by creating a multi-channel health product supply and retail system.

Key Dates

Keywords

Healthcare, Wine, China, Revenue, Net Loss, Financial Results, Annual Report